Drug treatment for spinal muscular atrophy types II and III
about
The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy modelsWhole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585.Treatment of spinal muscolar atrophy with intrathecal mesenchymal cells.Treatment Advances in Spinal Muscular Atrophy.
P2860
Drug treatment for spinal muscular atrophy types II and III
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Drug treatment for spinal muscular atrophy types II and III
@ast
Drug treatment for spinal muscular atrophy types II and III
@en
Drug treatment for spinal muscular atrophy types II and III
@en-gb
Drug treatment for spinal muscular atrophy types II and III
@nl
type
label
Drug treatment for spinal muscular atrophy types II and III
@ast
Drug treatment for spinal muscular atrophy types II and III
@en
Drug treatment for spinal muscular atrophy types II and III
@en-gb
Drug treatment for spinal muscular atrophy types II and III
@nl
prefLabel
Drug treatment for spinal muscular atrophy types II and III
@ast
Drug treatment for spinal muscular atrophy types II and III
@en
Drug treatment for spinal muscular atrophy types II and III
@en-gb
Drug treatment for spinal muscular atrophy types II and III
@nl
P2093
P2860
P1476
Drug treatment for spinal muscular atrophy types II and III
@en
P2093
Alexander FJE Vrancken
John HJ Wokke
Renske I Wadman
Susan T Iannaccone
Wendy MJ Bosboom
P2860
P356
10.1002/14651858.CD006282.PUB3
P577
2011-12-07T00:00:00Z